摘要:
A method of producing an alcohol, comprises reducing an aldehyde or a ketone with a hydridosilatrane. The reducing is carried out with an activator.
摘要:
The present invention provides a series of spirally configured cis-stilbene/fluorene hybrid materials, which are spirally-configured cis-stilbene/fluorene derivatives having glass transition temperatures ranged from 105° C. to 130° C., decomposition temperatures ranged from 385° C. to 415° C., reversible electron transport property, and balanced charges motilities. Moreover, a variety of experimental data have proved that the yellow fluorescent, the green phosphorescent, the yellow phosphorescent, and the red phosphorescent OLEDs using this spirally configured cis-stilbene/fluorene derivatives as the electron transport layers having hole blocking functions can indeed show excellent EQE, current efficiency, power efficiency, maximum luminance, and device lifetime performances much better than the conventional or commercial yellow fluorescent, green phosphorescent, yellow phosphorescent, and red phosphorescent OLEDs.
摘要:
A method to generate cyclic hydrocarbons from farnesene to increase both the density and net heat of combustion of the product fuels. The high density hydrocarbons produced by this method have applications for missile, UAV, jet, and diesel propulsion.
摘要:
A compound for controlling blood glucose level has a structure shown in Formula I: wherein R5-R8 are as defined herein. A method for controlling blood glucose level includes administering to a subject in need thereof a compound of Formula I. The method further includes administering to the subject a GLP-1 receptor ligand. The compound and the GLP-1 receptor ligand may be administered together. The compound may be Galanal A or Galanal B. The GLP-1 receptor ligand may be GLP-1 or exendin-4.
摘要翻译:用于控制血糖水平的化合物具有式I所示的结构:其中R5-R8如本文所定义。 用于控制血糖水平的方法包括向有需要的受试者施用式I的化合物。该方法还包括向受试者施用GLP-1受体配体。 化合物和GLP-1受体配体可以一起施用。 该化合物可以是Galanal A或Galanal B. GLP-1受体配体可以是GLP-1或毒蜥外泌肽-4。
摘要:
The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1—(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30, etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.
摘要:
This invention relates to benzocycloheptene derivatives having novel structure. More particularly, it relates to new benzocycloheptene derivatives and pharmaceutically acceptable salts thereof, their production processes, a pharmaceutical composition containing the same and a use thereof for the manufacture of medicaments.
摘要:
Novel tricyclic compounds of formula I as defined in the specification, a process for their preparation and their use for the preparation of optically active or racemic colchicine and thiocolchicine derivatives.
摘要:
A method of producing an alcohol, comprises reducing an aldehyde or a ketone with a hydridosilatrane. The reducing is carried out with an activator.
摘要:
A compound for controlling blood glucose level has a structure shown in Formula I: wherein R5-R8 are as defined herein. A method for controlling blood glucose level includes administering to a subject in need thereof a compound of Formula I. The method further includes administering to the subject a GLP-1 receptor ligand. The compound and the GLP-1 receptor ligand may be administered together. The compound may be Galanal A or Galanal B. The GLP-1 receptor ligand may be GLP-1 or exendin-4.
摘要翻译:用于控制血糖水平的化合物具有式I所示的结构:其中R5-R8如本文所定义。 用于控制血糖水平的方法包括向有需要的受试者施用式I的化合物。该方法还包括向受试者施用GLP-1受体配体。 化合物和GLP-1受体配体可以一起施用。 该化合物可以是Galanal A或Galanal B. GLP-1受体配体可以是GLP-1或毒蜥外泌肽-4。
摘要:
The present disclosure provides methods of preparing glucagon-like peptide-1 (GLP-1) receptor modulators, such as compounds of Formula (II) or (VI), or intermediates thereof. The compounds that may be prepared by the described methods are useful for regulating blood glucose levels and/or treating a disease mediated by a GLP-1 receptor (e.g., diabetes).